machineMD

At the intersection of neuroscience and ophthalmology, machineMD combines VR & AI, using the eye as a window to the brain.

neos® launched as a Class I medical device in Switzerland, USA and UK in April 2024, with first devices delivered to neurologists, ophthalmologists and optometrists. machineMD also launched a research use only device for specialists to generate data with specific patient populations.

Our medical advisory board contains board certified ophthalmologists and neurologists from Switzerland and the USA, soon to be extended to the UK.

Abnormalities in eye and pupil movements are important clinical indicators for the diagnosis and monitoring of neurological disorders including Multiple Sclerosis, brain tumors, and stroke, however expert examinations are reserved for tertiary care specialists with 6 month+ waiting lists.

Current clinical practice involves manual eye exams, comprising
time-intensive processes with qualitative results and misdiagnosis rates of 50%, leading to unnecessary procedures for 80% and significant harm for 26% of those patients.

machineMD introduces neos®, a breakthrough, fully automated non-invasive medical device for eye and pupil examinations that provides doctors with sensitive measurement data that can be used when assessing and monitoring ophthalmic and neurological disorders.

neos® is the first device that systematically generates eye movement and pupilometry data, essential for the long-term pathway to creating validated digital biomarkers for specific indications such as Multiple Sclerosis and Parkinson's Disease.

neos® launched with two business models to suit the complex healthcare reimbursement landscape:

CapEx pricing includes device purchase of $39k, plus annual warranty. This mirrors existing high-end ophthalmic equipment and fits within typical hospital budgets.

OpEx pricing includes a lower device purchase of $9k, plus a pay-per-use fee of $10/exam. This fits within existing reimbursement codes and best suits independent doctors and small clinics.

We see the opportunity to increase the pay-per-use pricing as we add more analysis to the device with respect to specific indications.

Global Eddies 2023
MassChallenge 2023
DayOne Health 4.0 2023/4
IMD Startup Competition 2023
Swissnex Boston, UK, and South Korea 2022-24